Produktname:4-((4-Methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)aniline
IUPAC Name:4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)aniline
- CAS：694499-26-8
- Molekulare Formel：C13H18F3N3
- Reinheit：95%+
- Katalognummer：CM169811
- Molekulargewicht：273.3
Nur für den Einsatz in Forschung und Entwicklung..
Produkt-Details
- CAS-Nr.:694499-26-8
- Molekulare Formel:C13H18F3N3
- Schmelzpunkt:-
- SMILES-Code:NC1=CC=C(CN2CCN(C)CC2)C(C(F)(F)F)=C1
- Dichte:
- Katalognummer:CM169811
- Molekulargewicht:273.3
- Siedepunkt:
- Mdl-Nr.:MFCD09909924
- Lagerung:Keep in dark place, store at 2-8°C.
Category Infos
- Piperazines
- Piperazine is an organic compound consisting of a six-membered ring containing two nitrogen atoms in opposite positions in the ring. The chemical formula of piperazine is C4H10N2, and it is an important pharmaceutical intermediate. Pyrimidines and piperazines are known to be the backbone of many bulk compounds and important core structures for approved drugs; studies have shown that combining a pyridine ring with a piperazine moiety within a single structural framework enhances biological activity.
- Benzenes
- Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.
Column Infos
- Olverembatinib
- Ascentage Pharma announced that updated results from three studies of olverembatinib, have been released in posters at the 2024 European Hematology Association Hybrid Congress, taking place in Madrid, Spain.
Olverembatinib (HQP1351) is an oral, third-generation BCR-ABL1 tyrosine kinase inhibitor (TKI) developed by Ascentage Pharma for the treatment of chronic myeloid leukaemia (CML), acute myeloid leukaemia, acute lymphoblastic leukaemia (ALL) and solid tumours, including gastrointestinal stromal tumours (GIST). Olverembatinib is an ATP binding-site inhibitor of wild type BCR-ABL1 kinase and a broad spectrum of BCR-ABL1 mutants, including mutant T315I, which confers resistance against all first- and second-generation TKIs.
Suche 
+86 21 5895 0110 
